FDA Warning Letter: Major CGMP & Sterile Manufacturing Violations 483

Table of Contents

FDA Warning Letter: Major CGMP, Aseptic Processing and Sterile Manufacturing Violations

This FDA warning letter identifies significant Current Good Manufacturing Practice (CGMP) deficiencies involving the manufacture of sterile injectable drug products. FDA determined that the firm’s methods, facilities, controls, and quality systems did not adequately conform to CGMP requirements under 21 CFR Parts 210 and 211. FDA therefore considered the affected drug products adulterated under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act.

The FDA warning letter highlights serious concerns involving inadequate investigations, endotoxin and bioburden control, failed media fills, poor aseptic practices, visible particulate contamination, facility and equipment design, environmental monitoring, process simulation, and overall pharmaceutical quality systems.

The FDA warning letter is particularly important for sterile pharmaceutical manufacturers because the observations demonstrate how weaknesses in contamination control, aseptic processing, investigation systems, and Quality Unit oversight can potentially affect product quality and patient safety.

Key Findings in the FDA Warning Letter

The major observations described in this FDA warning letter include:

Inadequate investigations of deviations, failures, and complaints
Inadequate investigation of endotoxin failures
Media-fill and aseptic process simulation deficiencies
Poor aseptic technique and cleanroom behavior
Extrinsic biological particulate contamination
Inadequate visual inspection systems
Deficiencies in facility and equipment design
Inadequate environmental monitoring and contamination-control systems
Inadequate Quality Unit and pharmaceutical quality-system oversight
Repeat CGMP deficiencies and need for comprehensive remediation
Product recalls and significant regulatory consequences

1. Inadequate Investigation and Root Cause Analysis

One of the most significant findings in this FDA warning letter concerns the firm’s investigation system.

FDA found that investigations did not consistently establish data-supported root causes, adequately document the investigation, expand the investigation to potentially affected products, or verify CAPA effectiveness.

FDA specifically identified concerns involving endotoxin test failures associated with famotidine injection. The firm had experienced bioburden action-limit failures, yet affected batches were released after passing finished-product testing. Subsequent testing of retained finished products identified an endotoxin failure, and three famotidine injection batches were ultimately recalled.

The FDA warning letter emphasizes that passing final product test results should not be used as the sole justification for dismissing significant manufacturing or microbiological signals.

Key lessons for pharmaceutical manufacturers

An effective investigation should include:

Immediate containment where appropriate
Scientific root-cause analysis
Assessment of potential product impact
Appropriate investigation scope
Review of related batches and products
Quality Unit oversight
CAPA development
CAPA effectiveness verification
Investigation trending
Retrospective review where systemic issues are suspected

FDA requested an independent retrospective review of critical investigations, including deviations, complaints, OOS/OOL results, and specification failures.

2. Endotoxin and Bioburden Control Deficiencies

The FDA warning letter places significant emphasis on endotoxin contamination risk in sterile injectable products.

FDA noted that the firm experienced bioburden action-limit failures and subsequently identified endotoxin failures in retained finished-product samples.

The warning letter emphasizes that atypical or excessive bioburden levels should be treated as important contamination signals requiring prompt investigation and appropriate risk assessment.

FDA requested a comprehensive evaluation of the firm’s endotoxin contamination prevention program covering areas such as:

Containers and closures
Ingredients
Water or relevant manufacturing systems
Process controls
Equipment design
Preventive maintenance
Repairs
Manufacturing environment
Environmental monitoring
CAPA

For sterile injectable products, inadequate control of endotoxin and pyrogen risks can have serious patient-safety implications.

3. Media Fill and Aseptic Process Simulation Failures

Another major observation in this FDA warning letter involves inadequate media-fill studies.

FDA reported media-fill failures on aseptic manufacturing lines in September and October 2024, as well as additional failures on a Restricted Access Barrier System line in April and October 2025. The investigations attributed the failures primarily to deficient aseptic techniques but did not adequately evaluate why the firm’s aseptic observer program failed to detect these practices during commercial manufacturing.

FDA also determined that the media fills did not adequately simulate the actual worst-case aseptic manufacturing conditions.

Problems included:

Insufficient simulation of maximum interventions
Inadequate documentation of inherent interventions
Insufficient media-fill batch sizes
Failure to adequately represent actual commercial operations
Inadequate intervention tracking
Insufficient worst-case evaluation

The FDA warning letter therefore demonstrates the importance of designing media fills to realistically challenge the actual aseptic process.

4. Poor Aseptic Technique and Cleanroom Behavior

The FDA warning letter also identifies serious concerns regarding aseptic practices and cleanroom behavior.

FDA observed practices that could increase contamination risks within critical ISO 5 processing areas.

Examples included:

Improper operator movements
Contact with barriers
Inappropriate handling of sterile tubing
Frequent high-risk interventions
Inadequate material handling
Deficiencies in operator practices
Insufficient supervisory oversight

FDA concluded that the firm’s response did not adequately address fundamental design and operational weaknesses in its aseptic processing lines.

For sterile manufacturing, operator behavior is a critical component of contamination control. Even a technically qualified facility can remain vulnerable if personnel practices introduce contamination risks into critical processing areas.

5. Extrinsic Biological Particulate Contamination

A particularly serious observation in the FDA warning letter concerns extrinsic biological contamination, including hair.

FDA reported that beginning in May 2022, the firm documented at least nine incidents involving extrinsic contamination during visible particulate inspection. The contamination was described as free-floating and in direct contact with drug product.

FDA was concerned that the firm did not initiate timely investigations and did not adequately address why affected commercial batches were not rejected.

The FDA warning letter requested:

Comprehensive investigation of biological particulate events
Retrospective review of relevant investigations
Evaluation of potentially affected products
CAPA effectiveness assessment
Assessment of incoming packaging components
Review of stopper supplier quality
Evaluation of retained samples where appropriate

This finding demonstrates the importance of treating biological particulate contamination as a potentially critical quality and sterility-assurance concern.

6. Inadequate Visual Inspection Program

The FDA warning letter identifies deficiencies in the firm’s visual inspection program for sterile injectable products.

FDA determined that the visual inspection system was not adequately capable of ensuring that sterile injectable products were essentially free from visible particulate and other defects.

FDA identified concerns involving:

Inadequate probability of detection
Inconsistent detection of visible particulates
Insufficient defect classification
Inadequate defect limits
Inadequate qualification of inspection systems
Insufficient evaluation of different particulate types and sizes
Inadequate assessment of products already on the market

FDA emphasized that visual inspection is a probabilistic process and that inspection systems must be appropriately qualified and capable of reproducibly detecting relevant defects.

The FDA warning letter also recommended that inspection programs incorporate product-specific knowledge, process experience, deviation data, complaint information, recall data, and quality risk management.

7. Facility and Equipment Design Deficiencies

The FDA warning letter also identifies deficiencies in the design of aseptic processing lines and associated facility controls.

FDA observed processing lines requiring frequent interventions and activities that could compromise protection of the ISO 5 critical areas.

Concerns included:

Inadequate barrier protection
Frequent high-risk interventions
Equipment and tubing configurations that increased contamination risks
Inadequate separation of critical areas
Facility-layout concerns
Ergonomic deficiencies
Insufficient protection of critical processing operations

FDA stated that the firm’s response did not provide sufficient corrective actions for the fundamental design weaknesses of the existing aseptic processing lines.

8. Environmental Monitoring and Contamination Control

The FDA warning letter requested an independent and comprehensive review of the firm’s environmental monitoring program.

The assessment was expected to address:

Environmental monitoring limits
Sampling methods
Sampling locations
Sampling frequencies
Trend analysis
Investigation of adverse trends
Deviation management
CAPA
Detection of potential contamination hazards

An effective environmental monitoring program should provide meaningful information about the state of environmental control and help detect trends before they become significant product-quality problems.

9. Quality System Deficiencies

Another important part of this FDA warning letter is the finding that the firm’s overall pharmaceutical quality systems were inadequate.

FDA referred to the need for stronger implementation of quality-system and risk-management principles, including those described in FDA’s quality-system guidance.

The firm’s remediation program was expected to address:

Root-cause analysis
CAPA effectiveness
Investigation quality
Quality Unit oversight
Management responsibility
Quality risk management
Environmental monitoring
Contamination control
Process simulation
Supplier oversight
Complaint and recall systems

The FDA warning letter therefore indicates that FDA viewed the observations as systemic rather than isolated manufacturing events.

10. CGMP Consultant and Comprehensive Audit

Due to the nature of the violations and repeat deficiencies, FDA recommended that the firm engage a qualified consultant under 21 CFR 211.34.

The consultant should conduct a comprehensive six-system CGMP audit and evaluate whether corrective and preventive actions have been completed and are effective.

FDA also made clear that hiring a consultant does not transfer regulatory responsibility away from the company.

Executive management remains responsible for resolving deficiencies and maintaining sustained CGMP compliance.

11. Product Recall and Regulatory Consequences

The FDA warning letter describes a significant recall-related development.

On July 9, 2026, FDA discussed voluntary recall actions with the firm after identifying concerns involving biological particulate contamination and CGMP deficiencies.

The firm subsequently committed to recalling six batches, with recalls initiated on July 16, 2026, involving products including:

Glycopyrrolate Injection, USP
Lidocaine HCl Injection, USP
Ropivacaine Hydrochloride Injection, USP
Lidocaine HCl Injection, USP

The FDA warning letter states that unresolved violations may result in additional regulatory consequences, including:

Withholding of Export Certificates
Withholding approval of new applications or supplements
Continued regulatory scrutiny
Follow-up inspection
Potential refusal of affected products
Additional regulatory action where appropriate

FDA also stated that products manufactured under conditions that do not conform to CGMP may be detained or refused admission into the United States.

Also read – FDA Warning Letter: Major CGMP, Quality System and OTC Drug Violations

Key Lessons from the FDA Warning Letter

This FDA warning letter provides several important lessons for sterile pharmaceutical manufacturers.

1. Investigate deviations thoroughly

Every significant deviation, complaint, OOS/OOL result, and process failure should be investigated scientifically and promptly.

2. Do not rely only on finished-product testing

Passing sterility, endotoxin, or other final-product tests does not necessarily eliminate the need to investigate upstream manufacturing failures or contamination signals.

3. Strengthen media-fill programs

Media fills should accurately represent commercial operations and include appropriate worst-case interventions.

4. Control aseptic behavior

Personnel practices, interventions, material movement, and cleanroom behavior must be continuously monitored and controlled.

5. Strengthen visual inspection

Visual inspection systems should be scientifically qualified and capable of detecting relevant particulate defects.

6. Treat biological contamination seriously

Extrinsic biological contamination should trigger appropriate investigation, risk assessment, product impact assessment, and CAPA.

7. Strengthen Quality Unit oversight

The Quality Unit must have sufficient authority, independence, resources, and expertise.

8. Address systemic causes

CAPA should address systemic root causes rather than simply correcting individual observations.

FDA Warning Letter – Inspection Readiness Checklist

Pharmaceutical companies can use the following areas when preparing for an FDA inspection:

OOS/OOL investigations
Deviation investigations
Complaint investigations
CAPA effectiveness
Media-fill qualification
Aseptic process simulation
Environmental monitoring
Contamination control strategy
Visible particulate inspection
Operator qualification
Cleanroom behavior
Facility and equipment design
Sterility assurance
Endotoxin control
Supplier qualification
Quality Unit oversight
Batch-release procedures
Recall readiness
Quality risk management
Internal CGMP audits

Conclusion

This FDA warning letter demonstrates the importance of an integrated pharmaceutical quality system for sterile drug manufacturing.

The observations involve interconnected areas including investigations, endotoxin control, media fills, aseptic processing, visible particulate inspection, contamination control, facility design, environmental monitoring, Quality Unit oversight, CAPA, and management responsibility.

The most important lesson from this FDA warning letter is that pharmaceutical manufacturers must build quality into the entire manufacturing process rather than relying primarily on final-product testing.

For companies manufacturing sterile injectable products for the U.S. market, the findings provide valuable lessons for improving CGMP compliance, contamination control, sterility assurance, aseptic processing, FDA inspection readiness, investigation systems, and pharmaceutical quality management.

A sustainable remediation program should identify systemic root causes, establish scientifically justified CAPA, verify CAPA effectiveness, strengthen management oversight, and provide objective evidence that the manufacturing process remains in a state of control.

Reference Warning Letter Date – 09/22/2026 Issued to Fresenius Kabi USA LLC for CGMP/Finished Pharmaceuticals/Adulterated by Center for Drug Evaluation and Research (CDER)

Disclaimer

Educational & Awareness Purpose Only:
This article has been prepared for learning, training, educational, and pharmaceutical industry awareness purposes only. The information presented in this article is based on and/or summarized from publicly available information published on the official U.S. Food and Drug Administration (FDA) website, including FDA Warning Letters.

For the original and most up-to-date information, readers should refer directly to the official FDA Warning Letters database and related FDA publications.

This article is not an official FDA publication, communication, guidance, regulatory decision, or statement of the U.S. Food and Drug Administration. PharmGuidances is not affiliated with, endorsed by, or representing the FDA.

The information provided should not be used as a substitute for official FDA documents, applicable laws and regulations, regulatory guidance, legal advice, compliance advice, or professional consultation. It should not be relied upon for making regulatory, legal, manufacturing, quality, or business decisions.

Official Reference:
FDA Warning Letters – U.S. Food and Drug Administration

Post Views: 13